EMA Withdrawn: Lenalidomide Krka d.d. (lenalidomide hydrochloride hydrate) — Krka, d.d., Novo mesto

View source ↗

Summary

The EMA withdrew lenalidomide hydrochloride hydrate (Krka) from the market for multiple indications including multiple myeloma, follicular lymphoma, and myelody…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma Follicular
• Multiple Myeloma
• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide Krka d.d. (lenalidomide hydrochloride hydrate) (lenalidomide hydrochloride hydrate)

Snippet

Status: Withdrawn. Therapeutic area: Multiple Myeloma;Lymphoma, Follicular;Myelodysplastic Syndromes. MAH: Krka, d.d., Novo mesto. Decision date: 13/12/2021